Cancer clinical trials in the region Nouvelle-Aquitaine

248 currently recruiting clinical trials

If you are a doctor and would like find matching clinical trials for you patients, create an account or log in

If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial

Phase 1 / Phase 2 Stomach and esophageal cancer #NCT06710132

[PROCEADE PanTumor ] Étude de l'ADC M9140 anti-CEACAM5 chez des participants atteints de tumeurs solides avancées - Sous-étude GC

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic 1 2 Chemotherapy

HER2 Systemic Treatment-Naive

Institut Bergonié (Bordeaux)

EMD Serono Research & Development Institute, Inc.

Phase 1 / Phase 2 Lung cancer #NCT06710132

[PROCEADE PanTumor ] Étude de l'ADC M9140 anti-CEACAM5 chez des participants atteints de tumeurs solides avancées - Sous-étude CBNPC

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic 1 2 3 or more Chemotherapy Targeted therapy

Systemic Treatment-Naive

Institut Bergonié (Bordeaux)

EMD Serono Research & Development Institute, Inc.

Phase 1 / Phase 2 Endometrial cancer #NCT04585750

[PYNNACLE] Evaluation du PC14586 chez les patients atteints de tumeurs solides avancées hébergeant une mutation TP53 Y220C

Locally Advanced Metastatic TP53 1 2 3 or more

KRAS G12C KRAS non G12C Systemic Treatment-Naive

Institut Bergonié (Bordeaux)

PMV Pharmaceuticals, Inc

Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04585750

[PYNNACLE] Evaluation du PC14586 chez les patients atteints de tumeurs solides avancées hébergeant une mutation TP53 Y220C

Locally Advanced Metastatic TP53 1 2 3 or more

KRAS G12C KRAS non G12C Systemic Treatment-Naive

Institut Bergonié (Bordeaux)

PMV Pharmaceuticals, Inc

Phase 1 / Phase 2 Lung cancer #NCT05592626

[START-001] Etude d'une molécule de fusion d'anticorps bifonctionnelle ciblant le récepteur sélectif des cellules T (TCR) STAR0602 chez des participants atteints de tumeurs solides avancées

NSCLC (Non-Small Cell Lung Cancer) Metastatic MSI/dMMR 1 2 3 or more

Institut Bergonié (Bordeaux)

Marengo Therapeutics, Inc.

Phase 1 / Phase 2 Lung cancer #NCT06162221

Étude des combinaisons d'inhibiteurs du RAS(ON) chez les patients atteints d'un CBNPC avancé muté par le RAS - Sous étude B

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic HRAS KRAS G12C KRAS non G12C KRAS G12D NRAS

Systemic Treatment-Naive Systemic Treatment-Naive

Institut Bergonié (Bordeaux)

Revolution Medicines, Inc.

Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT03093116

[TRIDENT-1] Étude du REPOTRECTINIB (TPX-0005) chez des patients atteints de tumeurs solides avancées présentant des réarrangements ALK, ROS1 ou NTRK1-3

Metastatic NTRK-1/2/3 1 2 3 or more Targeted therapy

Systemic Treatment-Naive

Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers)

Turning Point Therapeutics, Inc.

Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT03526835

Étude de l'anticorps bispécifique MCLA-158 chez des patients atteints de tumeurs solides avancées

Adenocarcinoma Locally Advanced Metastatic 1 Chemotherapy

BRAF KRAS G12C KRAS non G12C NRAS Systemic Treatment-Naive

Centre Hospitalier Universitaire de Bordeaux (Bordeaux)

Merus

Phase 1 / Phase 2 Breast cancer #NCT04143711

[DF1001-001] Étude du DF1001 chez des patients atteints de tumeurs solides avancées

HER2 Negative HR Positive Locally Advanced Metastatic 1 2 3 or more

Systemic Treatment-Naive

Groupe Hospitalier Saint André (Bordeaux)

Dragonfly Therapeutics

Phase 1 / Phase 2 Breast cancer #NCT04143711

[DF1001-001] Étude du DF1001 chez des patients atteints de tumeurs solides avancées

HER2 Low HER2 Positive Locally Advanced Metastatic 1 2 3 or more Targeted therapy Antibody Drug Conjugates (ADC)

Systemic Treatment-Naive

Groupe Hospitalier Saint André (Bordeaux)

Dragonfly Therapeutics